National Association of Testing Authorities, Australia
Scope of Accreditation
NSW Health Pathology
Scope of Accreditation
Molecular Medicine Laboratory
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
24 Jan 2027
Last Activity Date
29 Jun 2022
Service | Product | Determinant |
---|---|---|
Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-acetylcholine receptor antibodies (AChR) |
Anti-muscle specific kinase antibodies (MuSK) | ||
Molecular genetics - DNA extraction | Amniotic fluid; Blood; Buccal swabs; Chorionic villus tissue | DNA storage for future analyses; Viable DNA; Viable DNA for sequencing |
Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes | Blood; Extracted DNA | Charcot-Marie-Tooth neuropathy; Copy number variation (CNV); Friedreich's ataxia (FRDA, FA); Hereditary spastic paraplegia; Inherited disorders |
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Blood; Extracted DNA | Charcot-Marie-Tooth neuropathy; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Facioscapulohumeral muscular dystrophy; Friedreich's ataxia (FRDA, FA); Hereditary sensory neuropathy; Hereditary spastic paraplegia; Huntington's disease; Kennedy's disease (spinal and bulbar muscular atrophy); Motor neurone disease; Myotonic dystrophy; Oculopharyngeal muscular dystrophy; Spinocerebellar ataxia |
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Whole exome sequencing studies for inherited (germline) DNA/RNA changesExcludes sequencing | Blood; Extracted DNA | Ataxia; Congenital myasthenic syndrome; Copy number variation (CNV); Dystonia; Hereditary spastic paraplegia; Inherited disorders; Motor neurone disease; Neurodevelopmental delay; Nucleic acid analysis for unknown variants; Peripheral neuropathy; Variants in the nuclear genome |
Molecular genetics - Predictive genetic testing - Targeted genes | Blood | Charcot-Marie-Tooth neuropathy; Copy number variation (CNV); Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Facioscapulohumeral muscular dystrophy; Familial motor neurone disease - Amyotrophic lateral sclerosis (ALS); Friedreich's ataxia (FRDA, FA); Hereditary sensory neuropathy; Hereditary spastic paraplegia; Huntington's disease; Inherited disorders; Kennedy's disease (spinal and bulbar muscular atrophy); Myotonic dystrophy; Oculopharyngeal muscular dystrophy; Spinocerebellar ataxia |
Molecular genetics - Prenatal genetic testing (excluding non-invasive prenatal [genetic] screening) | Chorionic villus tissue; Extracted DNA | Charcot-Marie-Tooth neuropathy; Friedreich's ataxia (FRDA, FA); Hereditary sensory neuropathy; Hereditary spastic paraplegia; Huntington's disease; Kennedy's disease (spinal and bulbar muscular atrophy); Motor neurone disease; Myotonic dystrophy; Spinocerebellar ataxia |
Molecular genetics - Screening for an unknown mutation - Targeted genes | Blood; Extracted DNA | Charcot-Marie-Tooth neuropathy; Friedreich's ataxia (FRDA, FA); Hereditary sensory neuropathy; Hereditary spastic paraplegia; Motor neurone disease |
Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences; FASTQ files | Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2146
Site No.
24908
Print date
30 Nov 2024
END OF SCOPE